Overview of Development Pipeline of
Melanocortins for Treatment of Ocular Conditions and Role in
Resolving Inflammation
PL9643 Phase 3 Study Results in Dry Eye
Disease Currently Expected 2Q 2023
Palatin Progressing Development Programs in
Retinal and Front-of-the-Eye Indications Supported by Breakthrough
Science
CRANBURY, N.J., Sept. 29,
2022 /PRNewswire/ -- Palatin Technologies, Inc.
("Palatin") (NYSE American: PTN), a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin receptor system,
announced that Paul Kayne, Ph.D., Vice President of Biological
Sciences at Palatin, presented today at the Eyecelerator@AAO in
Chicago, IL. The presentation was
one of several in the "Eyecelerator@ AAO 2022 - Therapeutics
Showcase" general session.
Palatin's presentation included an overview of its development
pipeline of melanocortins for inflammatory conditions, including
several for ocular indications, and a summary of the role of
melanocortins in resolving inflammation. The presentation focused
on Palatin's research program with melanocortins in retinal
disease, including genomics and proteomics data supporting the
mechanism of action of melanocortins in the resolution of
inflammation in retinal tissue.
Eyecelerator is a partnership between the American Academy
of Ophthalmology (AAO) and the American Society of Cataract and
Refractive Surgery (ASCRS). Its mission is to connect
entrepreneurs, investors, companies, and physicians to advance
ophthalmic innovation through live conferences, virtual
programming, and a next-generation networking platform.
Palatin is currently conducting a Phase 3 clinical study with
PL9643 in patients for the treatment of dry eye disease with
initial results expected in the second quarter of calendar year
2023. PL9643 is a novel melanocortin agonist, delivered to the eye
topically via eyedrops. Palatin previously announced positive
results in its Phase 2 study of PL9643 for the treatment of DED.
Improvement in multiple signs and symptoms was achieved in the
moderate to severe patient population after 2 weeks of dosing and
at the 12-week visit. There were no safety signals identified and
PL9643 had excellent ocular tolerability.
Palatin has several additional research programs for treatments
of inflammatory conditions, both ocular and non-ocular. These
research programs include extensive studies on the genomics and
proteomics supporting the mechanism of action and role of
melanocortins on the resolution of inflammation.
American Academy of Ophthalmology
The Academy is the
world's largest association of eye physicians and surgeons. A
global community of 32,000 medical doctors, it protects sight and
empowers lives by setting the standards for ophthalmic education
and advocating for patients and the public. The Academy innovates
to advance the profession and to ensure the delivery of the
highest-quality eye care. Through its EyeSmart® articles on
AAO.org, the Academy provides the public with the most trusted
information about eye health. For more information,
visit aao.org.
ASCRS (American Society of Cataract and Refractive
Surgery)
ASCRS is an international educational society with
nearly 8,000 ophthalmic surgeons at every career stage. Its mission
is to empower anterior segment surgeons to improve the vision,
outcomes, and quality of life for their patients through innovative
approaches to education, advocacy, and philanthropy. For more
information, visit ascrs.org.
About Melanocortin Receptor Agonists and
Inflammation
The melanocortin receptor ("MCr") system has
effects on inflammation, immune system responses, metabolism, food
intake, and sexual function. There are five melanocortin receptors,
MC1r through MC5r. Modulation of these receptors, through use of
receptor-specific agonists, which activate receptor function, or
receptor-specific antagonists, which block receptor function, can
have medically significant pharmacological effects.
Many tissues and immune cells located in the eye (and other
places, for example the gut and kidney) express melanocortin
receptors, empowering our opportunity to directly activate natural
pathways to resolve disease inflammation.
About Palatin
Palatin is a biopharmaceutical company
developing first-in-class medicines based on molecules that
modulate the activity of the melanocortin receptor systems, with
targeted, receptor-specific product candidates for the treatment of
diseases with significant unmet medical need and commercial
potential. Palatin's strategy is to develop products and then form
marketing collaborations with industry leaders to maximize their
commercial potential. For additional information regarding Palatin,
please visit Palatin's website at www.Palatin.com and
follow Palatin on Twitter at @PalatinTech.
Forward-looking Statements
Statements in this press
release that are not historical facts, including statements about
future expectations of Palatin, such as statements about clinical
trial plans and potential results for PL9643, are "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and as
that term is defined in the Private Securities Litigation Reform
Act of 1995. Palatin intends that such forward-looking statements
be subject to the safe harbors created thereby. Such
forward-looking statements involve known and unknown risks,
uncertainties and other factors that could cause Palatin's actual
results to be materially different from its historical results or
from any results expressed or implied by such forward-looking
statements. Palatin's actual results may differ materially from
those discussed in the forward-looking statements for reasons
including, but not limited to, results of clinical trials,
regulatory actions by the FDA and other regulatory and the need for
regulatory approvals, Palatin's ability to fund development of its
technology and establish and successfully complete clinical trials,
the length of time and cost required to complete clinical trials
and submit applications for regulatory approvals, products
developed by competing pharmaceutical, biopharmaceutical and
biotechnology companies, commercial acceptance of Palatin's
products,
and other factors discussed in Palatin's periodic filings with
the Securities and Exchange Commission. Palatin is not responsible
for updating for events that occur after the date of this press
release.
Palatin Technologies® and Vyleesi® are registered trademarks of
Palatin Technologies, Inc.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/palatin-announces-presentation-at-the-eyeceleratoraao-2022-conference-301637262.html
SOURCE Palatin Technologies, Inc.